de Oliveira Amanda Priscila, Bernardo Cássia Rubia, Camargo Ana Vitória da Silveira, Ronchi Luiz Sérgio, Borim Aldenis Albaneze, de Mattos Cinara Cássia Brandão, de Campos Júnior Eumildo, Castiglioni Lílian, Netinho João Gomes, Cavasini Carlos Eugênio, Bestetti Reinaldo Bulgarelli, de Mattos Luiz Carlos
Laboratório de Imunogenética, Departamento de Biologia Molecular, Faculdade de Medicina de São José do Rio Preto, Avenida Brigadeiro Faria Lima, 5416, 15090-000, São José do Rio Preto, SP, Brazil.
Departamento de Cirurgia, Faculdade de Medicina de São José do Rio Preto, Avenida Brigadeiro Faria Lima, 5416, 15090-000, São José do Rio Preto, SP, Brazil.
PLoS One. 2015 Nov 23;10(11):e0141847. doi: 10.1371/journal.pone.0141847. eCollection 2015.
The clinical manifestations of chronic Chagas disease include the cardiac form of the disease and the digestive form. Not all the factors that act in the variable clinical course of this disease are known. This study investigated whether the CCR5Δ32 (rs333) and CCR5 59029 A/G (promoter region--rs1799987) polymorphisms of the CCR5 gene are associated with different clinical forms of chronic Chagas disease and with the severity of left ventricular systolic dysfunction in patients with chronic Chagas heart disease (CCHD). The antibodies anti-T. cruzi were identified by ELISA. PCR and PCR-RFLP were used to identify the CCR5Δ32 and CCR5 59029 A/G polymorphisms. The chi-square test was used to compare variables between groups. There was a higher frequency of the AA genotype in patients with CCHD compared with patients with the digestive form of the disease and the control group. The results also showed a high frequency of the AG genotype in patients with the digestive form of the disease compared to the other groups. The results of this study show that the CCR5Δ32 polymorphism does not seem to influence the different clinical manifestations of Chagas disease but there is involvement of the CCR5 59029 A/G polymorphism in susceptibility to the different forms of chronic Chagas disease. Besides, these polymorphisms do not influence left ventricular systolic dysfunction in patients with CCHD.
慢性恰加斯病的临床表现包括心脏型和消化型。并非所有影响该疾病临床病程变化的因素都为人所知。本研究调查了CCR5基因的CCR5Δ32(rs333)和CCR5 59029 A/G(启动子区域——rs1799987)多态性是否与慢性恰加斯病的不同临床类型以及慢性恰加斯心脏病(CCHD)患者左心室收缩功能障碍的严重程度相关。通过酶联免疫吸附测定法鉴定抗克鲁斯锥虫抗体。采用聚合酶链反应(PCR)和聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)来鉴定CCR5Δ32和CCR5 59029 A/G多态性。使用卡方检验比较组间变量。与患有消化型疾病的患者及对照组相比,CCHD患者中AA基因型的频率更高。结果还显示,与其他组相比,患有消化型疾病的患者中AG基因型的频率较高。本研究结果表明,CCR5Δ32多态性似乎不影响恰加斯病的不同临床表现,但CCR5 59029 A/G多态性与慢性恰加斯病不同类型的易感性有关。此外,这些多态性不影响CCHD患者的左心室收缩功能障碍。